1-7 of 7
Authors: Ultan McDermott
Journal Article
BIOM-60. BIOMARKER EVALUATION FOR IMIPRIDONE ONC206 REVEALS ClpP, ATF4, MYC, EGFR and HIF1 AS KEY PREDICTORS OF ANTI-CANCER EFFICACY Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii14–ii15, https://doi.org/10.1093/neuonc/noaa215.057
Published: 09 November 2020
Journal Article
EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii103, https://doi.org/10.1093/neuonc/noaa215.428
Published: 09 November 2020
Journal Article
EXTH-71. IND-ENABLING CHARACTERIZATION OF ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR NEURO-ONCOLOGY Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi97, https://doi.org/10.1093/neuonc/noz175.401
Published: 11 November 2019
Journal Article
PATH-42. EGFR-AMPLIFIED IDH-WILDTYPE GLIOBLASTOMAS SELDOM TRANSFORM INTO A HYPERMUTATED PHENOTYPE Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi168, https://doi.org/10.1093/neuonc/noy148.698
Published: 05 November 2018
Journal Article
EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi88, https://doi.org/10.1093/neuonc/noy148.366
Published: 05 November 2018
Journal Article
GENE-01. STABILITY OF ACTIONABLE MUTATIONS IN PRIMARY AND RECURRENT GLIOBLASTOMAS Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi92, https://doi.org/10.1093/neuonc/nox168.376
Published: 06 November 2017
Journal Article
GENE-13. AN INTEGRATED GENOMIC ANALYSIS OF ANAPLASTIC MENINGIOMA IDENTIFIES PROGNOSTIC MOLECULAR SIGNATURES Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi95, https://doi.org/10.1093/neuonc/nox168.388
Published: 06 November 2017
